Lexaria Bioscience (LEXX) details Nasdaq bid-price deficiency and delisting risk
Rhea-AI Filing Summary
Lexaria Bioscience Corp. reported receiving a Nasdaq Capital Market notification on August 4, 2026 that its common stock is subject to delisting for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price within a 180-day compliance period. The company had already completed a reverse stock split on August 3, 2026, after which its shares have been trading on Nasdaq under CUSIP 52886N604 with a bid price currently above the $1.00 requirement. Lexaria has requested a hearing and paid the related fee, which stays any suspension or delisting while it seeks to demonstrate renewed compliance, and it states that it expects to regain full compliance and maintain continuous Nasdaq trading.
Positive
- None.
Negative
- Nasdaq delisting risk: The company received a Nasdaq notice that its shares are subject to delisting for failing to regain compliance with the $1.00 minimum bid price requirement within the 180-day period.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum bid price requirement: $1.00 per share
Compliance period length: 180 days
Nasdaq notification date: August 4, 2026
+1 more
4 metrics
Minimum bid price requirement
$1.00 per share
Required bid price under Nasdaq Listing Rule 5550(a)(2)
Compliance period length
180 days
Compliance period under Nasdaq Listing Rule 5810(c)(3)(A)
Nasdaq notification date
August 4, 2026
Date Lexaria received Nasdaq delisting notification
Reverse stock split date
August 3, 2026
Date Lexaria completed reverse stock split to address bid price
Key Terms
Nasdaq Listing Rule 5550(a)(2), reverse stock split, Bid Price Requirement, delisted, +1 more
5 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"failure to regain compliance with Nasdaq Listing Rule 5550(a)(2)"
reverse stock split financial
"the Company completed a reverse stock split on August 3, 2026"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Bid Price Requirement financial
"being the requirement to maintain a $1.00 minimum bid price, (the “Bid Price Requirement”)"
A bid price requirement is a rule that specifies the minimum price a buyer must offer per share when making an official purchase proposal, tender offer, auction bid, or similar transaction. It matters to investors because it sets a floor for negotiations and valuation—like a reserve price in an auction—ensuring bids meet regulatory, contract or market standards and helping shareholders and markets judge whether an offer is fair or likely to succeed.
delisted regulatory
"it would be delisted from the Nasdaq, subject to any request for a hearing"
Delisted means a company's shares have been removed from a public stock exchange and are no longer traded on that venue. For investors this matters because it reduces ease of buying or selling the stock, cuts off regular price discovery and exchange oversight, and can signal regulatory or financial problems; it's like a product being pulled from a supermarket shelf and only available through harder-to-find channels.
hearing regulatory
"filed its request for a hearing and paid the required fee"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq issue did Lexaria Bioscience (LEXX) disclose on August 4, 2026?
Lexaria disclosed it received a Nasdaq notification that its stock is subject to delisting for failing to regain compliance with the $1.00 minimum bid price requirement within the 180-day compliance period.
Which Nasdaq rule is Lexaria Bioscience (LEXX) out of compliance with?
Lexaria reported non-compliance with Nasdaq Listing Rule 5550(a)(2), which sets the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
What step did Lexaria Bioscience (LEXX) take to address the Nasdaq bid-price deficiency?
To address the bid-price deficiency, Lexaria completed a reverse stock split on August 3, 2026, after which its common shares have been trading above the $1.00 minimum bid price on Nasdaq.
How is Lexaria Bioscience (LEXX) responding to the Nasdaq delisting notification?
Lexaria has filed a request for a hearing and paid the required fee, which stays any suspension or delisting while it seeks additional trading days to demonstrate compliance with Nasdaq rules.
Does Lexaria Bioscience (LEXX) expect its Nasdaq listing to continue?
The company stated it expects to regain compliance with Nasdaq rules before any potential hearing date and expects its shares to remain trading on the Nasdaq Capital Market without interruption.